Nothing seems to bother Seelos Therapeutics (NASDAQ:SEEL)


Earnings results for Seelos Therapeutics (NASDAQ:SEEL)

Seelos Therapeutics, Inc. is estimated to report earnings on 11/26/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.13.

Analyst Opinion on Seelos Therapeutics (NASDAQ:SEEL)

1 Wall Street analysts have issued ratings and price targets for Seelos Therapeutics in the last 12 months. Their average twelve-month price target is $12.00, predicting that the stock has a possible upside of 1,237.20%. The high price target for SEEL is $12.00 and the low price target for SEEL is $12.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Seelos Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $12.00, Seelos Therapeutics has a forecasted upside of 1,237.2% from its current price of $0.90. Seelos Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Seelos Therapeutics (NASDAQ:SEEL)

Seelos Therapeutics does not currently pay a dividend. Seelos Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Seelos Therapeutics (NASDAQ:SEEL)

In the past three months, Seelos Therapeutics insiders have not sold or bought any company stock. Only 7.60% of the stock of Seelos Therapeutics is held by insiders. Only 9.96% of the stock of Seelos Therapeutics is held by institutions.

Earnings and Valuation of Seelos Therapeutics (NASDAQ:SEEL

Earnings for Seelos Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.41) per share.

More latest stories: here